BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Global Pharmatech Entered Research Agreement With Kobayashi Pharmaceutical Co., Ltd.


4/18/2006 10:33:27 AM

JILIN, China, April 18 /Xinhua-PRNewswire/ -- Global Pharmatech, Inc. announced today that the R&D Director of Kobayashi Pharmaceutical Co., Ltd, Mr. Yoshihiro Yamaguchi, recently completed a trip to Natural Pharmatech (Jilin) Co., Ltd, a wholly-owned subsidiary of Global Pharmatech. Mr. Yoshihiro and his team inspected preclinical pharmacology and toxicology facilities and programs of Natural Pharmatech. Mr. Yoshihiro praised both the research equipment and experienced scientists and signed a new research service contract with Natural Pharmatech. He also expressed interest in a long term collaboration with the Company.

Dr. Xiaobo Sun, President and CEO of Global Pharmatech said, "We are delighted with this contract, which represents another step forward in our continuous effort to expand the global reach of our research services. Currently Natural Pharmatech has research partnerships with research institutions and pharmaceutical companies in Hong Kong, Singapore, Malaysia and Indonesia."

About Global Pharmatech

Global Pharmatech, through its subsidiaries, develops, manufactures and markets proprietary drugs that are based on Traditional Chinese Medicine using modern facilities and advanced R&D technologies. The company offers a full range of start-to-finish biotech services, from research and testing to manufacture and sale of liquid and solid dose products. The Company employs unique proprietary extraction methods and also licenses patents and technologies for botanical/biological drug products. Global Pharmatech's operations are currently based in the People's Republic of China with sales distribution centers in China, Malaysia, Singapore and Indonesia. For more information, please visit www.global-pharmatech.com

About Kobayashi Pharmaceutical

Kobayashi Pharmaceutical , located in Osaka, Japan, was established in 1919. Kobayashi has 1101 employees and 28 subsidiaries, including 17 in Japan, 6 in the US, 1 in the UK and 3 in Asia. The management policy has always been to provide people and society with wonderful comfort through "creativity and innovation." Over the years, the Company has expanded its scope, developing into a cluster of enterprises with three principal businesses: Consumer Products Operation, Wholesale Operation and Medical Devices Operation. Its operations also include medical research and the distribution of dietary supplements. In the fiscal year ended March 31, 2005, Kobayashi achieved increases in sales and profits for the seventh consecutive year since the introduction of consolidated accounting. For more information, please visit www.kobayashi.co.jp

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to successfully develop and commercialize products, competitive products in our key markets, changes in consumer demand for our products, legislative, regulatory and competitive developments and general economic conditions. Our SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

Contact: Zhuojun Li Investor Relations Global Pharmatech, Inc. Tel: (905)787-8225 Fax: (905)787-9711 Email: zhuojunli@global-pharmatech.com

Global Pharmatech, Inc.

CONTACT: Zhuojun Li, Investor Relations, Global Pharmatech, Inc.,+1-905-787-8225, Fax: +1-905-787-9711, zhuojunli@global-pharmatech.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES